SEARCH
= Registered usersPractitioner 2012; 256 (1755): 11-12
Intermittent ADT an option for advanced prostate cancer
31 Oct 2012
Compared with continuous treatment intermittent androgen deprivation therapy (ADT) can improve patients’ quality of life and does not adversely affect survival, a study in the NEJM concludes. [With external links to current evidence and summaries]
This article can be accessed only if you are a paid-up subscriber to The Practitioner.